Pfizer said Thursday that it is back in the race to get an effective weight-loss pill to market. The company’s announcement, however, did little to wash away the worries around its oral GLP-1 ...

The disappointing data Pfizer announced on its obesity pill are opening up opportunities for biotechs developing their own oral weight-loss drugs. Drugmakers are increasingly focused on the ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Doubling down on the bad news, Pfizer's journey into the weight loss drug market has fallen flat, as its twice-daily obesity-fighting pill danuglipron triggered nausea and other stomach issues in ...

Novo Nordisk and Eli Lilly are also working on developing their own next-gen weight loss drugs. Pfizer seems to be primarily focused on incretin pills. Weight loss medications that already on the ...